SOPHiA GENETICS SA Files 6-K Report
Ticker: SOPH · Form: 6-K · Filed: 2024-11-05T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, 6-K, disclosure
TL;DR
SOPHIA GENETICS (SOPH) filed a 6-K for Q3 2024, incorporating it into existing F-3 filings.
AI Summary
SOPHiA GENETICS SA filed a Form 6-K on November 5, 2024, for the period ending September 30, 2024. This report is a submission under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The filing is incorporated by reference into their existing Form F-3 registration statements.
Why It Matters
This filing provides updated information to the SEC, which is crucial for investors to stay informed about the company's ongoing disclosures and compliance.
Risk Assessment
Risk Level: low — This is a routine periodic filing (6-K) and does not appear to contain new material financial or operational information that would significantly alter risk.
Key Numbers
- 20240930 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 20241105 — Filing Date (The date the report was officially submitted to the SEC.)
Key Players & Entities
- SOPHiA GENETICS SA (company) — Filer of the report
- 001-40627 (company) — SEC File Number
- 333-266704 (company) — Form F-3 Registration Number
- 333-280060 (company) — Form F-3 Registration Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.
What is the reporting period for this 6-K filing?
The Conformed Period of Report is 20240930, meaning it covers the period ending September 30, 2024.
When was this Form 6-K filed?
This Form 6-K was filed on November 5, 2024.
How does this filing relate to SOPHiA GENETICS SA's existing registration statements?
This report is deemed to be incorporated by reference into the registrant's registration statements on Form F-3 (Registration No. 333-266704 and 333-280060).
What is the company's principal executive office address?
The principal executive office is located at La Pièce 12, CH-1180 Rolle, Switzerland.
Filing Stats: 255 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-11-05 06:38:06
Filing Documents
- q32024sophiageneticssa6-k.htm (6-K) — 15KB
- sophiageneticssaex991q32024.htm (EX-99.1) — 556KB
- sophiageneticssaex992q32024.htm (EX-99.2) — 297KB
- sophiageneticssaex993q32024.htm (EX-99.3) — 302KB
- 0001840706-24-000179.txt ( ) — 1171KB
Management's discussion and analysis of financial condition and results of operations
Management's discussion and analysis of financial condition and results of operations 99.3 Press Release dated November 5 , 2024